地特胰岛素联合瑞格列奈治疗初诊断2型糖尿病的临床疗效观察

目的:观察地特胰岛素联合瑞格列奈治疗初发2型糖尿病的临床疗效.方法:30例初次诊断的2型糖尿病患者采用地特胰岛素和瑞格列奈联合治疗,观察治疗12周前后的空腹血糖(FPG)、餐后2h血糖(2hPG)、糖化血红蛋白(HbA1C)、BMI变化.结果:与治疗前比较,治疗12周后患者的FBG、2hPG和HbA1C均明显降低(P＜0.05),无夜间低血糖发生.治疗前后体重无明显增加.结论:地特胰岛素联合瑞格列奈治疗初诊断2型糖尿病,血糖达标率高,低血糖发生率低,体重增加不明显.

The clinical efficacy of insulin detemir in combination with repaglinide for treating newly diagnosed type 2 diabetes

Objective: To investigate the clinical efficacy of insulin detemir in combination with repaglinide for treating newly diagnosed type 2 diabetes.Methods:Thirty newly diagnosed type 2 diabetes patients were received insulin detemir injection in combination with repaglinide.After 12 weeks treatment,the patients were observed how much indices of fasting blood glucose(FBG),2-hour postprandial blood glucose(2hPG),glycated hemoglobin(HbA1C) and body mass index(BMI)changed.Results:Compared with before treatment,FBG,2hPG and HbA1C were significantly decreased after 12 weeks of treatment(P<0.05),and there was no nocturnal hypoglycemia.There was no significant difference in BMI between before and after treatment.Conclusion:The treatment of detemir insulin in combination with repaglinide could efficiently improve diabetes care in newly diagnosed type 2 diabetes patients,with a lower incidence of hypoglycemia and no obvious increasing of body weight.